| Breast cancer early detection: A phased approach to implementation O Ginsburg, CH Yip, A Brooks, A Cabanes, M Caleffi, JA Dunstan Yataco, ... Cancer 126, 2379-2393, 2020 | 629 | 2020 |
| Assessment of the clinical benefit of cancer drugs receiving accelerated approval B Gyawali, SP Hey, AS Kesselheim JAMA Internal Medicine 179 (7), 906-913, 2019 | 281 | 2019 |
| Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis B Dhakal, A Szabo, S Chhabra, M Hamadani, A D’Souza, SZ Usmani, ... JAMA oncology 4 (3), 343-350, 2018 | 187 | 2018 |
| Financial toxicity of cancer treatment: moving the discussion from acknowledgement of the problem to identifying solutions A Desai, B Gyawali EClinicalMedicine 20, 2020 | 162 | 2020 |
| Evolution of the randomized clinical trial in the era of precision oncology JC Del Paggio, JS Berry, WM Hopman, EA Eisenhauer, V Prasad, ... JAMA oncology 7 (5), 728-734, 2021 | 159 | 2021 |
| Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional … H Naci, C Davis, J Savović, JPT Higgins, JAC Sterne, B Gyawali, ... bmj 366, 2019 | 141 | 2019 |
| An arm and a leg: the rising cost of cancer drugs and impact on access. NB Leighl, S Nirmalakumar, DA Ezeife, B Gyawali American Society of Clinical Oncology Educational book. American Society of …, 2021 | 140 | 2021 |
| An analysis of contemporary oncology randomized clinical trials from low/middle-income vs high-income countries JC Wells, S Sharma, JC Del Paggio, WM Hopman, B Gyawali, D Mukherji, ... JAMA oncology 7 (3), 379-385, 2021 | 138 | 2021 |
| Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs B Gyawali, SP Hey, AS Kesselheim EClinicalMedicine 21, 2020 | 131 | 2020 |
| Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey A Fundytus, M Sengar, D Lombe, W Hopman, M Jalink, B Gyawali, ... The Lancet Oncology 22 (10), 1367-1377, 2021 | 117 | 2021 |
| ReDO_DB: the repurposing drugs in oncology database P Pantziarka, C Verbaanderd, V Sukhatme, IR Capistrano, S Crispino, ... ecancermedicalscience 12, 2018 | 114 | 2018 |
| Association between progression‐free survival and patients’ quality of life in cancer clinical trials TJ Hwang, B Gyawali International journal of cancer 144 (7), 1746-1751, 2019 | 113 | 2019 |
| Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer N Hayashi, Y Ando, B Gyawali, T Shimokata, O Maeda, M Fukaya, H Goto, ... Oncology reports 35 (3), 1727-1731, 2016 | 104 | 2016 |
| Immunotherapy in non–small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence A Passaro, G Spitaleri, B Gyawali, F de Marinis Journal of Clinical Oncology 37 (22), 1863-1867, 2019 | 99 | 2019 |
| Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study B Gyawali, BN Rome, AS Kesselheim bmj 374, 2021 | 96 | 2021 |
| Efficacy, safety, and regulatory approval of Food and Drug Administration–designated breakthrough and nonbreakthrough cancer medicines TJ Hwang, JM Franklin, CT Chen, JC Lauffenburger, B Gyawali, ... Journal of Clinical Oncology 36 (18), 1805-1812, 2018 | 94 | 2018 |
| Prospective survey of financial toxicity measured by the comprehensive score for financial toxicity in Japanese patients with cancer K Honda, B Gyawali, M Ando, R Kumanishi, K Kato, K Sugiyama, S Mitani, ... Journal of global oncology 5, 1-8, 2019 | 79 | 2019 |
| A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and … B Gyawali, SP Hey, AS Kesselheim JAMA Network Open 1 (2), e180416-e180416, 2018 | 71 | 2018 |
| Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer B Gyawali, A Ota, Y Ando The New England Journal of Medicine 374 (5), 493, 2016 | 64* | 2016 |
| Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring B Gyawali, EGE De Vries, U Dafni, T Amaral, J Barriuso, J Bogaerts, ... ESMO open 6 (3), 100117, 2021 | 63 | 2021 |
Christopher M. Booth MD FRCPCProfessor of Oncology, Queen's UniversityVerifierad e-postadress på kgh.kari.net
